Related Experiment Videos
Oncogene amplifications in early-stage human prostate carcinomas
A Latil1, J C Baron, O Cussenot
1Laboratoire d'Oncogénétique, Centre René Huguenin, St-Cloud, France.
International Journal of Cancer
|December 1, 1994
Summary
This study investigated oncogene amplifications in prostate cancer. Researchers found no evidence of c-myc, int2/FGF3, or c-erbB2/neu gene amplification in early-stage prostate tumors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Oncogene amplifications are common in solid tumors, correlating with aggressive cancer.
- Specific oncogenes like c-myc, c-erbB2/neu, and the 11q13 region are frequently amplified in various adenocarcinomas.
Purpose of the Study:
- To determine the involvement of c-myc, int2/FGF3 (11q13 region), and c-erbB2/neu genes in prostate tumorigenesis.
- To investigate oncogene amplification in localized early-stage prostate carcinomas.
Main Methods:
- Analysis of tumor and peripheral lymphocyte DNA from 21 patients with early-stage prostate cancer.
- Southern-blot electrophoresis used to detect amplification of c-myc, c-erbB2/neu, and the 11q13 region (int2/FGF3).
Main Results:
- No amplification of the c-myc gene was detected in the analyzed prostate tumors.
- No amplification of the c-erbB2/neu gene was observed.
- No amplification of the 11q13 region (int2/FGF3) was found in the study cohort.
Conclusions:
- The investigated oncogenes (c-myc, c-erbB2/neu, int2/FGF3) do not appear to be amplified in localized early-stage prostate carcinomas.
- These specific amplifications may not play a significant role in the initial stages of prostate cancer development.